Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.
Company Details
- Employees
- 11
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Retension Pharmaceuticals Questions
Retension Pharmaceuticals's website is http://www.retensionpharmaceuticals.com
Retension Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/retension-pharmaceuticals
Retension Pharmaceuticals has
11 employees.
View email and phone details for 11
employees at Retension Pharmaceuticals.
Retension Pharmaceuticals's industry is
Biotechnology Research
Retension Pharmaceuticals's top competitors are
Pathalys Pharma,
Monod Bio,
Photonpharma,
Applied Therapeutics, Inc.,
Volastra Therapeutics,
Noveome Biotherapeutics, Inc.,
Bridgebio,
Response Pharmaceuticals,
Emergent Bioscience,
Talus Bio.
Retension Pharmaceuticals's categories are Biotechnology Research
Retension Pharmaceuticals's founding year is 2023
